Insulet Stock News

LAS VEGAS , Dec. 1, 2021 /PRNewswire/ -- DelveInsight''s Insulin Delivery Devices Market Insights and Forecast report provides the current and forecast Insulin Delivery Devices Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Insulin Delivery Devices Market. Some of the salient features from the Insulin Delivery Devices Market report: As per DelveInsight analysis, in terms of revenue share, APAC is predicted to register the fastest growth in the Insulin Delivery Devices market because of the high prevalence of diabetes. Major pharma players working proactively in the Insulin Delivery Devices Market include Becton, Dickinson and Company, Medtronic, Novo Nordisk A/S, Ypsomed Holding AG, Tandem Diabetes Care, Inc., Biocon Ltd., Eli Lilly and Company, Insulet Corporation, Abbott, Terumo, CeQur, EOFLOW CO., LTD, European Pharma Group BV, Roche, Sanofi, Hindustan Syringes & Medical Devices Ltd, Ocean ( Hangzhou ) Medical Technology Co Ltd, Owen Mumford , SOOIL Developments Co., Ltd, SUNGSHIM MEDICAL CO., LTD, and others.

Eastern Bank lifted its stake in Insulet Co. (NASDAQ:PODD) by 76.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 13,469 shares of the medical instruments suppliers stock after acquiring an additional 5,838 shares during the quarter. Eastern Banks holdings in Insulet were worth $3,828,000 []

NuWave Investment Management LLC trimmed its position in shares of Insulet Co. (NASDAQ:PODD) by 42.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 262 shares of the medical instruments suppliers stock after selling 195 shares during the quarter. NuWave Investment Management LLCs holdings in Insulet were worth $74,000 as of its most recent []

Exchange Traded Concepts LLC lessened its stake in shares of Insulet Co. (NASDAQ:PODD) by 0.4% during the third quarter, Holdings Channel.com reports. The fund owned 12,420 shares of the medical instruments suppliers stock after selling 50 shares during the period. Exchange Traded Concepts LLCs holdings in Insulet were worth $3,530,000 at the end of the []

Juncture Wealth Strategies LLC reduced its position in shares of Insulet Co. (NASDAQ:PODD) by 78.4% during the third quarter, Holdings Channel reports. The institutional investor owned 760 shares of the medical instruments suppliers stock after selling 2,751 shares during the period. Juncture Wealth Strategies LLCs holdings in Insulet were worth $216,000 as of its most []

Parametric Portfolio Associates LLC increased its stake in shares of Insulet Co. (NASDAQ:PODD) by 14.6% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 71,128 shares of the medical instruments suppliers stock after purchasing an additional 9,080 shares during the period. Parametric Portfolio Associates LLC owned 0.10% []

ACTON, Mass. --(BUSINESS WIRE)--Nov. 24, 2021-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at the virtual 45 th Nasdaq Investor Conference on Friday,

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management

Analysts forecast that Insulet Co. (NASDAQ:PODD) will post sales of $298.38 million for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Insulets earnings. The lowest sales estimate is $283.40 million and the highest is $308.50 million. Insulet posted sales of $246.10 million during the same quarter last year, which []

Berman Capital Advisors LLC increased its position in Insulet Co. (NASDAQ:PODD) by 151.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 965 shares of the medical instruments suppliers stock after purchasing an additional 581 shares during the quarter. Berman []

J.P. Morgan Stick to Their Buy Rating for Insulet

Insulet (PODD) reports better-than-expected revenues for third-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.

Insulet Corporation (PODD) CEO Shacey Petrovic on Q3 2021 Results - Earnings Call Transcript

Insulet (PODD) delivered earnings and revenue surprises of -9.09% and 1.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?